S-1/A: Aspira Womens Health Files Amendment No. 1 to Form S-1 for Potential $2 Million Stock Offering

Aspira Womens Health aims to raise up to $2 million through a common stock purchase agreement, as detailed in its amended S-1 filing.

Summary

• Aspira Womens Health has filed an amendment to its Form S-1 registration statement.
• The filing pertains to the potential resale of common stock by Triton Funds LP.
• The offering includes 354,988 commitment shares already issued and up to 42,328,042 shares issuable under a purchase agreement.
• The company entered into a common stock purchase agreement with Triton Funds LP on April 4, 2025.
• Under the agreement, Aspira can require Triton to purchase up to $2,000,000 of common stock until September 30, 2025.
• The purchase price per share will be 75% of the lowest daily VWAP during the five trading days prior to payment.
• Aspira intends to use the net proceeds for ongoing commercial activities, general corporate purposes, and working capital.
• The company's common stock was delisted from Nasdaq and is now quoted on the OTC Markets Pink Sheets under the symbol AWHL.
• Aspira is classified as a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is securing funding, the delisting from Nasdaq and reliance on the OTC Markets Pink Sheets are concerning. The high degree of risk associated with the company's securities also contributes to the lower sentiment score.

Positives

• The purchase agreement provides Aspira with a potential source of funding for commercial activities and working capital.
• Being a smaller reporting company allows Aspira to reduce certain disclosure requirements.
• The company has the ability to control the timing and amount of any sales of common stock to the Selling Stockholder.

Negatives

• The company's common stock was delisted from the Nasdaq Capital Market.
• The company's stock is now trading on the OTC Markets Pink Sheets, which may have an unfavorable impact on the stock price and liquidity.
• The company has incurred significant losses and negative cash flows from operations since inception and has an accumulated deficit of $531,397,000 as of December 31, 2024.

Risks

• Investing in the company's securities is highly speculative and involves a high degree of risk.
• The company may need to sell additional shares of its common stock or other securities in the future to meet its capital requirements, which could cause significant dilution.
• Failures by third-party payers to reimburse for the company's products and services or changes in reimbursement rates could materially and adversely affect the company's business, financial condition and results of operations.
• The company may not succeed in improving existing or developing additional diagnostic products, and, even if it does succeed in developing additional diagnostic products, the diagnostic products may never achieve significant commercial market acceptance.
• The diagnostics market is competitive, and the company may not be able to compete successfully, which would adversely impact its ability to generate revenue.
• The company is currently offering and developing multiple tests as LDTs and the FDAs newly-issued rule for LDTs, which will be phased in over a period of four years, will significantly change the regulatory landscape for LDTs.
• The company's diagnostic tests and software are subject to ongoing regulation by the FDA, and any delay by or failure of the FDA to authorize the company's diagnostic tests submitted to the FDA may adversely affect the company's business, results of operations and financial condition.
• If the company or its suppliers fail to comply with FDA requirements for production, marketing and post-market monitoring of its products, the company may not be able to market its products and services and may be subject to stringent penalties, product restrictions or recall.
• Changes in healthcare policy could increase the company's costs and adversely impact sales of and reimbursement for its tests, which would have an adverse effect on its business, financial condition and results of operations.
• The company is subject to environmental laws and potential exposure to environmental liabilities.
• The operation of Aspira Labs requires the company to comply with numerous laws and regulations, which is expensive and time-consuming and could adversely affect its business, financial condition and results of operations, and any failure to comply could result in exposure to substantial penalties and other harm to its business.
• The company's ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.
• If the company is unable to complete the required milestones under its federal award milestone-based funding agreement, its business, results of operations and financial condition will be adversely affected.
• If the company fails to maintain its rights to utilize intellectual property directed to diagnostic biomarkers, it may not be able to offer diagnostic tests using those biomarkers.
• If a third party infringes on the company's proprietary rights, the company may lose any competitive advantage it has as a result of diversion of its time, enforcement costs and the loss of the exclusivity of its proprietary rights.
• If others successfully assert their proprietary rights against the company, it may be precluded from making and selling its products or it may be required to obtain licenses to use their technology.
• The company's diagnostic efforts may cause it to have significant product liability exposure.
• Certain of the company's patent registrations will expire, which may cause it to have significant competition.
• Because the company's business is highly dependent on key executives and employees, its inability to recruit and retain these people could hinder its business plans.
• Business interruptions could limit the company's ability to operate its business.
• The operation of Aspira Labs and the company's Aspira Synergy business depends on the effectiveness and availability of its information systems, including the information systems it uses to provide services to its customers and to store employee data. If the company's information technology systems or those third parties upon which it relies or its data, are or were compromised, the company could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of its business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.
• The company selectively explores acquisition opportunities and strategic alliances relating to other businesses, products or technologies. The company may not be successful in integrating other businesses, products or technologies with its business. Any such transaction also may not produce the results it anticipates, which could adversely affect its business, financial condition and results of operations.
• Future litigation by or against the company could be costly and time-consuming to prosecute or defend.
• The sale and issuance of the company's common stock to the Selling Stockholder will cause dilution to its existing stockholders, and the sale of the shares of common stock acquired by the Selling Stockholder, or the perception that such sales may occur, could cause the price of its common stock to fall.
• You may experience immediate and substantial dilution.
• Investors who buy shares of the company's common stock at different times will likely pay different prices.
• The company's management team will have broad discretion over the use of the net proceeds from its sale of shares of common stock to the Selling Stockholder, if any, and you may not agree with how it uses the proceeds and the proceeds may not be invested successfully.
• The company's common stock is a penny stock, which may make it more difficult for investors to sell their shares of common stock due to suitability requirements.
• The company's common stock is currently traded on the OTC Markets Pink Sheets, which may have an unfavorable impact on its stock price and liquidity.
• Financial Industry Regulatory Authority (FINRA) sales practice requirements may also limit a stockholders ability to buy and sell the company's common stock, which could depress the price of its common stock.
• Since the company's common stock is currently quoted on the OTC Markets Pink Sheets its stockholders may face significant restrictions on the resale of its common stock due to state blue sky laws and the sale of common stock in this offering is subject to state blue sky laws.
• The liquidity and trading volume of the company's common stock may be low, and its ownership is concentrated, which could adversely impact the trading price of its common stock and its stockholders ability to obtain liquidity.
• The company's stock price has been, and may continue to be, highly volatile.
• Anti-takeover provisions in the company's charter, bylaws, other agreements and under Delaware law could make a third-party acquisition of the Company difficult.
• If the company raises additional capital in the future, your ownership in it could be diluted.
• Sales of a substantial number of its shares of common stock in the public market could cause its stock price to fall.
• Because the company does not currently intend to declare cash dividends on its shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of its common stock for any return on their investment.
• The exercise of the company's outstanding options and warrants will dilute stockholders and could decrease its stock price.

Future Outlook

Aspira intends to use the net proceeds received from the Purchase Agreement for ongoing commercial activities as well as general corporate purposes and working capital. The company expects to need to obtain additional financing in the future in order to fully fund all of its planned activities.

Industry Context

The announcement reflects the ongoing challenges faced by smaller biotech companies in maintaining Nasdaq listing compliance and securing funding for operations. The shift to the OTC Markets Pink Sheets may limit investor access and liquidity.

Comparison to Industry Standards

• It is difficult to compare Aspira's current situation to industry standards due to its delisting from Nasdaq and reliance on OTC Markets.
• Companies like Exact Sciences and Grail, which are developing multi-cancer early diagnostic tests, have significantly higher market capitalizations and access to capital.
• Smaller diagnostic companies often rely on strategic partnerships or acquisitions to achieve scale and market access, a path Aspira is also pursuing with its Aspira Synergy platform.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of new shares.
• Employees' stock options may be affected by the company's stock performance.
• Customers may see continued access to Aspira's diagnostic tests.
• Suppliers may benefit from the company's ongoing commercial activities.

Next Steps

• The company will continue to commercialize its existing and new technology.
• Aspira will distribute its tests through its decentralized technology transfer service platform, Aspira Synergy.
• The company plans to advocate for legislation and the adoption of its technology in professional society guidelines to provide broad access to its products and services.
• The company will continue to monitor developments closely and believe additional due process would be required if the activities contemplated by Novitas change the coverage determination for Ova1.

Key Dates

Keywords

common stock, stock offering, Triton Funds LP, purchase agreement, securities, AWHL, OTC Markets, dilution, risk factors, Aspira Womens Health